期刊
CANCER GENE THERAPY
卷 17, 期 12, 页码 893-905出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/cgt.2010.47
关键词
adenovirus; bone metastases; breast cancer; osteoprotegerin; virotherapy
类别
资金
- NIH [R01 CA108585, T32 CA075930, P30 AR046031, P50 CA089019]
- DOD [DAMD17-03-1-0256, W81XWH-04-1-0800]
- Susan G Komen Breast Cancer Foundation [BCTR0100406]
- University of Alabama at Birmingham, USA
Most patients with advanced breast cancer develop osteolytic bone metastases, which have numerous complications. Because current therapies are not curative, new treatments are needed. Conditionally replicating adenoviruses (CRAds) are anticancer agents designed to infect and lyse tumor cells. However, in spite of their promise as selective cancer therapeutics, replicating adenoviruses have shown limited efficacy in the clinical setting. We hypothesized that a CRAd armed with osteoprotegerin (OPG) would eradicate bone metastases of breast cancer both directly, by oncolysis, and indirectly, by inhibiting osteoclastic bone resorption, and thus reducing the tumor burden. We constructed an armed CRAd (Ad5-Delta 24-sOPG-Fc-RGD) by replacing viral E3B genes with a fusion of the ligand-binding domains of OPG and the Fc portion of human IgG1. Conditional replication was conferred by a 24-base pair deletion within E1A (Delta 24), which prevents the binding of E1A to the retinoblastoma tumor suppressor/cell cycle regulator protein and limits replication in normal cells. Enhanced infection of cells expressing low levels of the primary Ad5 receptor was conferred by incorporating an arginine-glycine-aspartic acid (RGD) peptide sequence into the fiber knob to mediate binding to alpha(v) integrins. After characterization of the armed CRAd, we demonstrated that infection of breast cancer cells by Ad5-Delta 24-sOPG-Fc-RGD both killed the infected cells by oncolysis and inhibited the formation of osteoclasts in an in vitro co-culture model. In a murine model of osteolytic bone metastases of breast cancer, the CRAd armed with shortened OPG (sOPG)-Fc reduced tumor burden in the bone and inhibited osteoclast formation more effectively than an unarmed CRAd. Cancer Gene Therapy (2010) 17, 893-905; doi: 10.1038/cgt.2010.47; published online 27 August 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据